Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.43 CAD
Change Today +0.03 / 7.50%
Volume 198.2K
MBX On Other Exchanges
As of 4:26 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

microbix biosystems inc (MBX) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/20/14 - C$0.90
52 Week Low
08/24/15 - C$0.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

microbix biosystems inc (MBX) Related Businessweek News

No Related Businessweek News Found

microbix biosystems inc (MBX) Details

Microbix Biosystems Inc. develops, manufactures, and sells biological products and technologies in North America, Europe, and internationally. The company manufactures and sells cell culture-based biological products, as well as infectious disease antigens. It offers infectious disease antigens, such as viral, bacterial, and parasitic products used in various applications, including immunodiagnostic assays; basic and applied research in virology, microbiology, cell biology, molecular biology, immunology, and pathology; as controls and calibrators for a range of medical devices; and for vaccine and antiviral research and development. In addition, the company provides adenovirus vectors, cells, and services to biopharmaceutical and biotechnology researchers and companies, as well as provides facility, technical, and production personnel for contract research and development. Its pipeline of technologies and products includes LumiSort semen sexing technology for the livestock industries; Kinlytic, a thrombolytic drug with various approved and potential applications, including the treatment of life-threatening blood clots, and VIRUSMAX, a proprietary technology for increasing virus yields in the manufacture of influenza vaccine. The company offers products for human health applications, namely in the vaccine, therapeutic, and diagnostic markets, as well as animal reproductive markets. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Founded in 1988

microbix biosystems inc (MBX) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: C$217.0K
Founder, Executive Chairman, Member of Audit ...
Total Annual Compensation: C$190.9K
Chief Financial Officer
Total Annual Compensation: C$190.8K
Senior Vice President of Sales, Business Deve...
Total Annual Compensation: C$174.8K
Vice President of Biopharmaceuticals
Total Annual Compensation: C$150.7K
Compensation as of Fiscal Year 2014.

microbix biosystems inc (MBX) Key Developments

Microbix Biosystems Inc. Reports Financial Results for the Third Quarter and Nine Months Ended June 30, 2015

Microbix Biosystems Inc. reported financial results for the third quarter and nine months ended June 30, 2015. Total revenue was $2,219,019 in the third quarter compared to $2,039,935 in the third quarter last year, or an increase of 9%. Operating income in the third quarter was $147,769 compared to an operating income of $294,561 in the third quarter of 2014. The lower operating income was the result of increased operating expenses to support the VIRUSMAX litigation during the quarter. Cash used in operations was $180,333 in the third quarter compared to $212,923 positive in the same period in 2014, primarily due to an increase in inventory in anticipation of higher shipments in the fourth quarter, as well as the trial production batches in the new Bioreactor manufacturing platform which is being commissioned this fall. Net income was $131,864 against $83,994 for the same period of last year. Net income per share was $0.001 against $0.003 for the same period of last year. The company reported total revenue of $6,759,752 in the first nine months of 2015 compared to $6,040,917 for the same period in 2014, or an increase of 12%. Operating income in the first nine months was $324,657 compared to $778,587 in the first nine months of 2014. The lower operating income resulted from increased operating expenses to support the VIRUSMAX litigation, which more than offset the impact of higher revenues in the first nine months of 2015 compared to the same period last year. Cash generated from operations in the first nine months was $511,008 compared to $191,226 of cash used in operations in the first nine months of 2014. Net income was $312,539 against $257,987 for the same period of last year. Net income per share was $0.003 against $0.008 for the same period of last year.

Microbix Biosystems Inc. Introduces Two New Toxoplasma Gondii Products

Microbix Biosystems Inc. announced the commercial introduction of two new Toxoplasma Gondii products targeted at immunoassay manufacturers looking for improved sensitivity and specificity of diagnostic tests. Toxoplasma is a common parasitic infection spread primarily by cats and contaminated food. While toxoplasma infection is usually asymptomatic in healthy people, it can cause serious complications to a developing fetus and to the immune compromised (e.g. HIV infected patients). Toxoplasma testing is part of the TORCH diagnostic panel (Toxoplasma, Rubella, CMV, Herpes) routinely administered to expectant mothers in the first trimester of pregnancy. The new antigens available from Microbix will be used in IgG and IgM antibody detection tests produced by most of the diagnostic manufacturers. Many of these companies already use antigens produced by Microbix.

Microbix Biosystems Inc. Presents at 5th LD Micro Invitational Conference, Jun-03-2015 08:00 AM

Microbix Biosystems Inc. Presents at 5th LD Micro Invitational Conference, Jun-03-2015 08:00 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States. Speakers: Vaughn C. Embro-Pantalony, Chief Executive Officer, President, Director, Member of Audit Committee and Member of Human Resources, Compensation & Governance Committee.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MBX:CN C$0.43 CAD +0.03

MBX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MBX.
View Industry Companies

Industry Analysis


Industry Average

Valuation MBX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.5x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MICROBIX BIOSYSTEMS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at